论文部分内容阅读
目的对比放疗联合替莫唑胺与放疗联合靶向药物治疗肺癌脑转移的临床效果和毒副作用。方法本研究选取经病理证实肺癌脑转移患者40例,将其随机分为观察组和对照组,每组各20例,观察组采用6MV-X全脑照射DT40Gy/20次,常规分割DT2Gy/次,同时联合替莫唑胺治疗,同时联合靶向药物治疗为对照组,观察两组患者的临床治疗效果以及毒副作用。结果在疗效以及复发中位时间的对比中,观察组明显优于对照组,两组存在差异有统计学意义,P<0.05。同时在毒副作用的对比中,两组对比差异无统计学意义,P>0.05。结论采用放疗联合替莫唑胺治疗非小细胞肺癌脑转移患者具有应用价值,可以有效的延长复发中位时间,同时毒副作用相对较小,值得在临床中推广应用。
Objective To compare the clinical effects and toxicities and side effects of radiotherapy combined with temozolomide and radiotherapy combined with targeted drugs in the treatment of brain metastases of lung cancer. Methods Forty patients with pathologically confirmed brain metastases of lung cancer were selected and randomly divided into observation group (20 cases) and control group (20 cases). The observation group received DT40Gy / 20 times 6MV-X whole brain irradiation and routinely divided DT2Gy / time , Combined with temozolomide treatment, combined with targeted drug treatment as a control group, the clinical efficacy of the two groups were observed and the side effects. Results in the efficacy and recurrence of the median time comparison, the observation group was significantly better than the control group, there was a significant difference between the two groups, P <0.05. At the same time in the comparison of toxic and side effects, no significant difference between the two groups, P> 0.05. Conclusion The combination of radiotherapy and temozolomide in the treatment of patients with brain metastasis of non-small cell lung cancer can prolong the median time to relapse and has relatively small toxic and side effects. It is worthy of clinical application.